C07K 14/7051
T-cell receptor -cd3 complex
Official title: {T-cell receptor (TcR)-CD3 complex}
C07K14/7051 (T-cell receptor -cd3 complex) appears on 3,229 US grants and 7,408 published applications in this corpus.
Search patents in C07K- Granted patents
- 3,229
- Published applications
- 7,408
- Assignees
- 1,667
- Inventors
- 9,578
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 3 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 5 | 0 |
| 1994 | 5 | 0 |
| 1995 | 3 | 0 |
| 1996 | 8 | 0 |
| 1997 | 17 | 0 |
| 1998 | 20 | 0 |
| 1999 | 24 | 0 |
| 2000 | 26 | 0 |
| 2001 | 13 | 1 |
| 2002 | 15 | 20 |
| 2003 | 8 | 18 |
| 2004 | 6 | 21 |
| 2005 | 5 | 17 |
| 2006 | 8 | 25 |
| 2007 | 9 | 10 |
| 2008 | 13 | 19 |
| 2009 | 6 | 28 |
| 2010 | 12 | 27 |
| 2011 | 17 | 29 |
| 2012 | 13 | 30 |
| 2013 | 16 | 37 |
| 2014 | 15 | 50 |
| 2015 | 32 | 68 |
| 2016 | 44 | 150 |
| 2017 | 58 | 246 |
| 2018 | 118 | 372 |
| 2019 | 214 | 547 |
| 2020 | 299 | 672 |
| 2021 | 304 | 839 |
| 2022 | 321 | 966 |
| 2023 | 345 | 867 |
| 2024 | 433 | 933 |
| 2025 | 473 | 814 |
| 2026 | 315 | 602 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2Cellectis
- Anti-Nectin-4 antibody, conjugate including the same, and application thereof6 Oct 2026US 12,753,230 B2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Compositions and methods for modifying a target nucleic acid6 Oct 2026US 12,753,412 B2The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Timp3-derived teipp neoantigens and uses thereof8 Oct 2026US 2026/0306599 A1
- Fusion proteins of il-24 and immunostimulatory cytokines, nk cells expressing il-24 or fusion proteins, and methods of use thereof8 Oct 2026US 2026/0308218 A1Virginia Commonwealth University
- Multi-receptor natural killer cells8 Oct 2026US 2026/0308225 A1Board of Regents, The University of Texas System
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998